Coverage
-
August 25, 2015
An Indiana federal judge on Tuesday ruled that Teva Parenteral Medicines Inc.'s proposed labeling for a generic version of the cancer drug Alimta would cause physicians to infringe Eli Lilly & Co.'s vitamin-regimen patent.
2 other articles on this case.
View all »